Gain insights on the practical components of SGLT2is including patient selection, initiation, dosing, sequencing, and monitoring to successfully incorporate these agents into practice. 

Accreditation Statement 

In accordance with ACCME policy, prior to participating in this activity, you must review the information on this page. 

In accordance with ACCME policy, prior to participating in this activity, you must review the information on this page. 

Joint Accreditation 

 
In support of improving patient care, the American College of Cardiology Foundation (ACCF) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 
 

Credit Statement 
Physicians  

The ACCF designates this Certified Patient Case for a maximum of up to 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
 
While offering the CME credits noted above, this program is not intended to provide extensive training or certification in the field. 

 
MOC Information

Successful completion of this certified activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. 
 
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 
 

Nurses 
The ACCF designates this educational activity for a maximum of 0.25continuing nursing education contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity. 
 
Physician Assistants 
The American College of Cardiology Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits.  

Approval is valid until July 31, 2025. PAs should only claim credit commensurate with the extent of their participation. 

To request credit, you must: 

1. Read all text and view all tables and/or figures in the case for which you wish to receive credit. 
2. Answer the questions in each case for which you wish to claim credit. After you have answered all the questions, click on the Exam Summary button.  
3. Click the Claim Credit button and answer the evaluation questions in the pop-up window. 
4. Enter the total amount of time you actually spent in the activity in the box provided. Please note that you may only claim once for each module in this activity. Click Submit. 
5. You will receive a message that your request has been submitted and a link to view your certificate. You may view and download the certificate when you receive the message, you may also view it at any time in the My Transcript section of My ACC. 

This certified activity may contain links to other educational resources such as clinical trial summaries, journal articles, guidelines, etc., that may not be certified. Please note that clicking on the links provided to view these resources will open new windows, which are outside of this certified activity. 

Learner Objectives  

Upon completion of this activity, you should be able to:  

1. Identify the clinical indications and key considerations for selection of SGLT2 inhibitors for heart failure patients  
2. Establish a contemporary prescribing timeline including initiation, dosing, and monitoring of SGLT2 inhibitors 

Target Audience  

This course is intended for cardiovascular team clinicians including physicians, nurse practitioners, physician assistants and pharmacists who manage patients with heart failure. 
 
Important Dates 
Date of Release: August 1, 2022 
Term of Approval/Date of Expiration: July 31, 2025 

 
Acknowledgement 
This activity is supported by an independent educational grant from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. 

Faculty: 
Nosheen Reza, MD, FACC 

Peer Reviewer: 
Alison Bailey, MD, FACC 
Shashank Sinha, MD, FACC